Christophe Bourdon, Orphazyme CEO

Or­p­hazyme CEO de­parts for Leo Phar­ma as both com­pa­nies face ma­jor re­struc­tur­ings

Some­one else, it seems, will get the op­por­tu­ni­ty of try­ing to steer Or­p­hazyme back to its for­mer meme­land glo­ry.

In a bit of Dan­ish biotech mu­si­cal chairs, Or­p­hazyme CEO Christophe Bour­don is leav­ing the rare dis­ease biotech to be­come CEO of the der­ma­tol­ogy-fo­cused Leo Phar­ma, the com­pa­nies an­nounced. Bour­don’s de­par­ture, set for April 1, will come bare­ly a year af­ter he joined, al­though it was not an un­event­ful one.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.